Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026)
Forte Biosciences (FBRX) posted quarterly Other Non Operating Income of $676000.0 for Q1 2026, up 44.44% year-over-year from $468000.0 in Q1 2025, and up 150.71% quarter-over-quarter from -$1.3 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Other Non Operating Income for 9 consecutive years, with $676000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 44.44% year-over-year to $676000.0; the TTM figure through Mar 2026 stood at $374000.0 (up 452.83% YoY), while the FY2025 annual figure was $166000.0, up 187.37% from the prior year.
- Other Non Operating Income grew to $676000.0 in Q1 2026 per FBRX's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $701000.0 in Q3 2025 and bottomed at -$1.3 million in Q4 2025.
- Historically, Other Non Operating Income has averaged $23117.6 across 5 years, with a median of $138000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 1034.78% in 2023 and fell as far as 515.0% in 2023.
- Forte Biosciences' Other Non Operating Income stood at -$100000.0 in 2022, then plunged by 515.0% to -$615000.0 in 2023, then tumbled by 81.79% to -$1.1 million in 2024, then dropped by 19.23% to -$1.3 million in 2025, then surged by 150.71% to $676000.0 in 2026.
- Business Quant data shows FBRX's Other Non Operating Income at $676000.0 in Q1 2026, -$1.3 million in Q4 2025, and $701000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.47 Mn |
| Mar 31, 2026 | 676,000.00 |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 701,000.00 |
| Jun 30, 2025 | 330,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 307,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -615,000.00 |
| Sep 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | -100,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | -42,000.00 |
| Sep 30, 2021 | -52,000.00 |